Trulicity® (dulaglutide) is now indicated as an adjunct to diet, exercise, and standard of care therapy to reduce the risk of non-fatal stroke in adults with type 2 diabetes mellitus who have multiple cardiovascular risk factors or established cardi
(World News Science)

TORONTO, Sept. 22, 2020 (GLOBE NEWSWIRE) -- On September 11, 2020, Health Canada approved Trulicity® (dulaglutide) to reduce the risk of non-fatal stroke in adults with type 2 diabetes mellitus who have multiple cardiovascular risk factors or established cardiovascular disease, as an adjunct to diet, exercise, and standard of care therapy. This decision makes Eli Lilly and Company`s Trulicity the first and only GLP1 receptor agonist (RA) approved to provide a cardiovascular benefit in people with multiple CV risk factors or with established cardiovascular disease. The new indication reflects the differentiated patient population of REWIND, the Trulicity cardiovascular outcomes trial. The...